Ross Kedl, PhD

Professor of Immunology & Microbiology
University of Colorado

Ross KedlDr. Kedl received his PhD in 1997 in the Department of Laboratory Medicine and Pathology at the University of Minnesota in Minneapolis. Before joining the Faculty at the University of Colorado, Dr. Kedl was at 3M Pharmaceuticals working in their small molecule immune response modifier program. In his three years there, he spearheaded efforts at developing novel vaccine adjuvants, resulting in numerous publications and patents in the area of vaccine technology. Dr. Kedl returned to the academic sector in 2004 by joining the faculty in the Integrated Department of Immunology at the University of Colorado Health Sciences Center and National Jewish Medical Research Center where he continues to pursue the discovery and development of novel and clinically applicable vaccine technology. He is also the founder of a start-up pharmaceutical company, ImmuRx Inc., which focuses on developing therapeutic vaccines against chronic infectious diseases, such as HIV and cancer.

Biography from University of Colorado.

IDIGH Calendar

<<  <  July 2020  >  >>
 Mo  Tu  We  Th  Fr  Sa  Su 
    1  2  3  4  5
  6  7  8  9101112
13141516171819
20212223242526
2728293031  

Latest IDIGH Publications

  1. Duffy, S. C., Srinivasan, S., Schilling, M. A., Stuber, T., Danchuk, S. N., Michael, J. S., Venkatesan, M., Bansal, N., Maan, S., Jindal, N., Chaudhary, D., Dandapat, P., Katani, R., Chothe, S., Veerasami, M., Robbe-Austerman, S., Juleff, N., Kapur, V. & Behr, M. A.
    (2020)
    .
    Reconsidering Mycobacterium bovis as a proxy for zoonotic tuberculosis: a molecular epidemiological surveillance study
    .
    The Lancet. Microbe
    ,
    vol
    .
    1
    ,
    p
    .
    e66-e73
    .
  2. Stallworthy, G., Dias, H. M. & Pai, M.
    (2020)
    .
    Quality of tuberculosis care in the private health sector
    .
    Journal of clinical tuberculosis and other mycobacterial diseases
    ,
    vol
    .
    20
    ,
    p
    .
    100171
    .
  3. Noël, K. C., Papenburg, J., Lacroix, J., Quach, C., O'Donnell, S., Gonzales, M., Willson, D. F., Gilfoyle, E., McNally, J. D., Reynolds, S., Kazzaz, Y., Kawaguchi, A., Sato, M., Kongkiattikul, L., Leteurtre, S., Dubos, F., Karaca, Y., Chiusolo, F., Piva, J., Dendukuri, N., Fontela, P. S. & Canadian Critical Care Trials Group (CCCTG) and the Pediatric Lung Injury and Sepsis Investigators (PALISI) Network.
    (2020)
    .
    International Survey on Determinants of Antibiotic Duration and Discontinuation in Pediatric Critically Ill Patients
    .
    Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies
  4. Saha-Chaudhuri, P., Rabin, C., Tchervenkov, J., Baran, D., Morein, J. & Sapir-Pichhadze, R.
    (2020)
    .
    Predicting Clinical Outcome in Expanded Criteria Donor Kidney Transplantation: A Retrospective Cohort Study
    .
    Canadian journal of kidney health and disease
    ,
    vol
    .
    7
    ,
    p
    .
    2054358120924305
    .
  5. Ladouceur, A., Tessier-Cloutier, B., Clarke, A. E., Ramsey-Goldman, R., Gordon, C., Hansen, J. E. & Bernatsky, S.
    (2020)
    .
    Cancer and Systemic Lupus Erythematosus
    .
    Rheumatic diseases clinics of North America
    ,
    vol
    .
    46
    ,
    p
    .
    533-550
    .
More publications